Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karen L. Zimowski"'
Autor:
Rodney M. Camire, Miguel A. Escobar, Navdeep Jhita, Michelle D. Ho, Angel A Rivera, Christopher B. Doering, Karen L. Zimowski, Christine L. Kempton, Gabriela Denning, Jordan E Shields, Julie Wechsler, Teodolinda Petrillo
Publikováno v:
Journal of Thrombosis and Haemostasis
Background Elucidating the molecular pathogenesis underlying the East Texas Bleeding Disorder (ET) led to the discovery of alternatively spliced F5 transcripts harboring large deletions within exon 13. These alternatively spliced transcripts produce
Autor:
Karen L. Zimowski, Glaivy Batsuli, Corinna L. Schultz, Catherine E. McGuinn, Shipra Kaicker, Yasmina L. Abajas
Publikováno v:
Journal of Thrombosis and Haemostasis. 18:2551-2556
BACKGROUND Congenital factor X deficiency (FXD) is a rare bleeding disorder that often presents with severe bleeding in the neonatal period. Long-term prophylaxis with infusions of FX-containing products is recommended in patients with FXD and a pers
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 25(5)
INTRODUCTION The formation of neutralizing antifactor VIII (fVIII) antibodies, called inhibitors, is the most common complication in modern haemophilia A care. Novel non-factor replacement therapies, such as emicizumab, have sought to address the lim
Autor:
Suchitra S. Acharya, Judith Aeschlimann, Ahmad Al-Huniti, Ana G. Antun, Suzanne A. Arinsburg, Scott T. Avecilla, Burak Bahar, Debra Jo Bailey, Glaivy Batsuli, Henny H. Billett, Evan M. Bloch, Michael A. Briones, James B. Bussel, Marcus A. Carden, Wayne L. Chandler, Dong Chen, Marie Csete, Adam Cuker, Melissa M. Cushing, Jennifer Davila, Robert A. DeSimone, Roger Y. Dodd, Nancy M. Dunbar, Amy L. Dunn, Patrick A. Erdman, Ivo M.B. Francischetti, Richard O. Francis, Yelena Z. Ginzburg, Elizabeth A. Godbey, Ruchika Goel, Amit Gokhale, Yitz Goldstein, Jed B. Gorlin, Cheryl A. Goss, Janis R. Hamilton, Jeanne E. Hendrickson, Rong He, Christopher D. Hillyer, Eldad A. Hod, Yen-Michael S. Hsu, Heather A. Hume, Jack Jacob, Shilpa Jain, Florencia G. Jalikis, Alexandra Jimenez, Shawn M. Jobe, Cassandra D. Josephson, Matthew S. Karafin, Louis M. Katz, Christine L. Kempton, Debra A. Kessler, Margarita Kushnir, Michele P. Lambert, Marissa Li, Deepa Manwani, Irina Maramica, Susanne Marschner, Emeline Masson Frenet, Catherine E. McGuinn, Shannon L. Meeks, Connie H. Miller, Caterina P. Minniti, William B. Mitchell, Grace F. Monis, Theresa Nester, Philip Norris, Angela Novotny, Monika Paroder-Belenitsky, Shibani Pati, Kim Peck, Huy P. Pham, Allyson Pishko, Eva D. Quinley, Sabrina Racine-Brzostek, Lynsi Rahorst, Hanna Rennert, Joseph S.A. Restivo, Morayma Reyes Gil, Liz Rosenbaum-Marinaro, Mikhail Roshal, Sara Rutter, Bruce S. Sachais, Surbhi Saini, Susmita N. Sarangi, William J. Savage, Andromachi Scaradavou, Joseph Schwartz, Jansen N. Seheult, Eric Senaldi, Salima Shaikh, Anjali Sharathkumar, Beth H. Shaz, Patricia A. Shi, Sierra C. Simmons, Elizabeth M. Staley, Emily K. Storch, Donna Strauss, Yvette C. Tanhehco, Aaron A.R. Tobian, Christopher A. Tormey, Mary Townsend, Duc Q. Tran, Nancy L. Van Buren, Sunitha Vege, Randall Velliquette, Francesca Vinchi, Rona S. Weinberg, Stuart P. Weisberg, Connie M. Westhoff, Michael White, Anne M. Winkler, Lucia R. Wolgast, Kalinda Woods, Lina Y. Dimberg, Mark H. Yazer, Carolyn T. Young, Patricia E. Zerra, Karen L. Zimowski
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d072d8239a33073b8804f97eeef2514
https://doi.org/10.1016/b978-0-12-813726-0.01002-3
https://doi.org/10.1016/b978-0-12-813726-0.01002-3
Autor:
Jenny McDaniel, Karen L. Zimowski, Paulette Bryant, Shannon L. Meeks, Glaivy Batsuli, Kelly Tickle, Robert F. Sidonio
Publikováno v:
Blood. 134:1126-1126
Introduction : Emicizumab is a novel humanized bispecific antibody that mimics the function of activated coagulation factor VIII (fVIII). It has significantly changed the management of patients with hemophilia A and inhibitors by achieving baseline h
Publikováno v:
Sickle Cell Disease and Hematopoietic Stem Cell Transplantation ISBN: 9783319623276
As overall outcomes from hematopoietic stem cell transplantation (HSCT) continue to improve, the repertoire of nonmalignant indications for transplant also continues to expand. Nonmalignant conditions accounted for approximately 30% of all transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a868032cdb725b6e2fd5963989844f92
https://doi.org/10.1007/978-3-319-62328-3_7
https://doi.org/10.1007/978-3-319-62328-3_7
Publikováno v:
Blood. 132:634-634
Introduction: The formation of neutralizing anti-factor VIII (fVIII) antibodies, called inhibitors, is a challenging complication in hemophilia A care. While novel non-factor therapies significantly reduce bleeding symptoms in patients with hemophili
Autor:
Glaivy Batsuli, Shannon L. Meeks, Robert F. Sidonio, Jatin Rana, Michael U. Callaghan, Kelly Tickle, Karen L. Zimowski, Mark T. Reding
Publikováno v:
Blood. 132:635-635
Introduction: Patients with severe hemophilia A and anti-factor VIII (fVIII) antibodies (inhibitors) are at risk of significant bleeding during invasive procedures. Prior to the introduction of the bispecific humanized antibody, emicizumab, the stand